TY - JOUR
T1 - The Epilepsy Foundation's 4th Biennial Epilepsy Pipeline Update Conference
AU - French, Jacqueline A.
AU - Schachter, Steven C.
AU - Sirven, Joseph
AU - Porter, Roger
N1 - Funding Information:
The authors gratefully acknowledge the dedication and editorial assistance of Kim Macher, VP, Epilepsy Therapy Project, Epilepsy Foundation, as well as the speakers, and the support of Phil Gattone and Warren Lammert, as well as everyone who helped to make the meeting a success.
Funding Information:
J. French is President of the Epilepsy Study Consortium. All consulting is done on behalf of the consortium, and fees are paid to the consortium. The NYU Comprehensive Epilepsy Center receives salary support from the consortium. She has acted as a consultant for Acorda, Biotie, Brabant Pharma, Eisai Medical Research, GlaxoSmithKline, GW Pharma, Impax, Johnson and Johnson, Marathon Pharmaceuticals, Marinus, Neusentis, Novartis, Pfizer, Sage, Sunovion, SK Life Sciences, Supernus Pharmaceuticals, Takeda, UCB, Upsher-Smith, Ultragenyx, Vertex, Zynerba; has received grants and research from Acorda, Alexza, LCGH, Eisai Medical Research, Lundbeck, Pfizer, SK Life Sciences, UCB, Upsher-Smith, Vertex; and has received grants from NINDS, Epilepsy Therapy Project, Epilepsy Research Foundation, Epilepsy Study Consortium. She is on the editorial board of Lancet Neurology, Neurology Today, and Epileptic Disorders, and an associate editor of Epilepsia.
Publisher Copyright:
© 2015 Elsevier Inc.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - On June 5 and 6, 2014, the Epilepsy Foundation held its 4th Biennial Epilepsy Pipeline Update Conference, an initiative of the Epilepsy Therapy Project, which showcased the most promising epilepsy innovations from health-care companies and academic laboratories dedicated to pioneering and advancing drugs, biologics, technologies, devices, and diagnostics for epilepsy. Speakers and attendees included emerging biotech and medical technology companies, major pharmaceutical and device companies, as well as investigators and innovators at the cutting-edge of epilepsy. The program included panel discussions on collaboration between small and large companies, how to get products in need of funding to the marketplace, who is currently funding epilepsy and CNS innovation, and how the NIH facilitates early-stage drug development. Finally, the conference featured the third annual "Shark Tank" competition. The presentations are summarized in this paper, which is followed by a compilation of the meeting poster abstracts.
AB - On June 5 and 6, 2014, the Epilepsy Foundation held its 4th Biennial Epilepsy Pipeline Update Conference, an initiative of the Epilepsy Therapy Project, which showcased the most promising epilepsy innovations from health-care companies and academic laboratories dedicated to pioneering and advancing drugs, biologics, technologies, devices, and diagnostics for epilepsy. Speakers and attendees included emerging biotech and medical technology companies, major pharmaceutical and device companies, as well as investigators and innovators at the cutting-edge of epilepsy. The program included panel discussions on collaboration between small and large companies, how to get products in need of funding to the marketplace, who is currently funding epilepsy and CNS innovation, and how the NIH facilitates early-stage drug development. Finally, the conference featured the third annual "Shark Tank" competition. The presentations are summarized in this paper, which is followed by a compilation of the meeting poster abstracts.
KW - Devices
KW - Diagnostics
KW - Epilepsy
KW - Food and drug administration
KW - Innovation
KW - Pipeline
KW - Seizure
KW - Therapies
UR - http://www.scopus.com/inward/record.url?scp=84937977448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937977448&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2015.02.033
DO - 10.1016/j.yebeh.2015.02.033
M3 - Review article
C2 - 25922152
AN - SCOPUS:84937977448
VL - 46
SP - 34
EP - 50
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
SN - 1525-5050
ER -